About Halozyme Therapeutics, Inc.
https://www.halozyme.comHalozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.
CEO
Helen I. Torley M.B. Ch. B., M.R.C.P.
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 277
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Benchmark
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Morgan Stanley
Overweight
Wells Fargo
Equal Weight
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
DLD ASSET MANAGEMENT, LP
Shares:30M
Value:$2.19B
BLACKROCK INC.
Shares:17.62M
Value:$1.29B
BLACKROCK, INC.
Shares:12.86M
Value:$938.28M
Summary
Showing Top 3 of 748
About Halozyme Therapeutics, Inc.
https://www.halozyme.comHalozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $354.26M ▲ | $81.1M ▲ | $175.22M ▲ | 49.46% ▼ | $1.49 ▲ | $284.63M ▲ |
| Q2-2025 | $325.72M ▲ | $76.92M ▲ | $165.16M ▲ | 50.71% ▲ | $1.36 ▲ | $229.83M ▲ |
| Q1-2025 | $264.86M ▼ | $74.92M ▼ | $118.09M ▼ | 44.59% ▼ | $0.96 ▼ | $168.8M ▼ |
| Q4-2024 | $298.01M ▲ | $80.45M ▲ | $137.01M ▲ | 45.98% ▼ | $1.08 | $203.17M ▲ |
| Q3-2024 | $290.08M | $77.46M | $137.01M | 47.23% | $1.08 | $190.03M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $701.96M ▲ | $2.22B ▲ | $1.72B ▼ | $503.92M ▲ |
| Q2-2025 | $548.18M ▼ | $2.05B ▼ | $1.72B ▲ | $332.75M ▼ |
| Q1-2025 | $747.92M ▲ | $2.2B ▲ | $1.71B ▲ | $482.27M ▲ |
| Q4-2024 | $596.07M ▼ | $2.06B ▼ | $1.7B ▲ | $363.82M ▼ |
| Q3-2024 | $666.31M | $2.12B | $1.67B | $452.7M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $175.22M ▲ | $178.6M ▲ | $201.61M ▲ | $-22.4M ▲ | $357.8M ▲ | $175.57M ▲ |
| Q2-2025 | $165.16M ▲ | $99.71M ▼ | $84.79M ▲ | $-298.97M ▼ | $-114.47M ▼ | $98.15M ▼ |
| Q1-2025 | $118.09M ▼ | $154.22M ▼ | $-90.42M ▼ | $-3.32M ▲ | $60.48M ▲ | $153.27M ▼ |
| Q4-2024 | $137.01M ▲ | $178.47M ▲ | $29.48M ▲ | $-246.41M ▼ | $-38.47M ▼ | $175.41M ▲ |
| Q3-2024 | $137.01M | $115.38M | $-167.48M | $18.56M | $-33.55M | $113.86M |
Revenue by Products
| Product | Q4-2024 | Q3-2024 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 bulk rHuPH20 | $0 ▲ | $30.00M ▲ | $20.00M ▼ | $30.00M ▲ |
 Collaborative Agreements | $80.00M ▲ | $50.00M ▼ | $40.00M ▼ | $20.00M ▼ |
 Product | $140.00M ▲ | $90.00M ▼ | $180.00M ▲ | $150.00M ▼ |
 Royalty | $300.00M ▲ | $160.00M ▼ | $210.00M ▲ | $170.00M ▼ |
 Salesbased Milestone | $0 ▲ | $0 ▲ | $10.00M ▲ | $10.00M ▲ |
 Upfront fees | $0 ▲ | $30.00M ▲ | $0 ▼ | $0 ▲ |
CEO
Helen I. Torley M.B. Ch. B., M.R.C.P.
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 277
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Benchmark
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Morgan Stanley
Overweight
Wells Fargo
Equal Weight
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
DLD ASSET MANAGEMENT, LP
Shares:30M
Value:$2.19B
BLACKROCK INC.
Shares:17.62M
Value:$1.29B
BLACKROCK, INC.
Shares:12.86M
Value:$938.28M
Summary
Showing Top 3 of 748